Related Experiment Videos
[18F]fluoroestradiol radiation dosimetry in human PET studies
D A Mankoff1, L M Peterson, T J Tewson
1Departments of Radiology and Medical Oncology, University of Washington School of Medicine, Seattle, Washington 98195, USA.
Summary
Radiation dosimetry for [18F]16alpha-fluoroestradiol (FES) PET imaging in breast cancer patients shows well-accepted radiation risks. Organ doses are comparable to other nuclear medicine tests, confirming FES safety for estrogen receptor studies.
Area of Science:
- Nuclear medicine
- Radiopharmacology
- Medical imaging
Background:
- [18F]16alpha-fluoroestradiol (FES) is a positron emission tomography (PET) imaging agent used to study estrogen receptors.
- Estrogen receptor status is critical for breast cancer diagnosis and treatment.
Purpose of the Study:
- To estimate the radiation dosimetry of the FES PET imaging agent.
- To assess the safety and radiation risks associated with FES use in patients.
Main Methods:
- Radiation absorbed doses were calculated using the MIRD committee procedures.
- Time-dependent tissue concentrations were determined from blood samples and PET images in 49 patients.
- Effective dose equivalent was calculated using ICRP Publication 60 weights for the standard woman.
Main Results:
- The effective dose equivalent was 0.022 mSv/MBq.
- The liver received the highest organ dose (0.13 mGy/MBq), followed by the gallbladder and urinary bladder.
- Organ doses were found to be comparable to those of other common nuclear medicine tests.
Conclusions:
- FES is a valuable estrogen receptor-imaging agent for breast cancer studies.
- The radiation risks associated with FES PET imaging are within acceptable limits.
- The dosimetry data support the continued clinical use of FES.